FDA Expands Enzalutamide Approval to Earlier Prostate Cancer FDA Expands Enzalutamide Approval to Earlier Prostate Cancer

The expanded approval makes enzalutamide the first and only approved androgen receptor signaling inhibitor in the nonmetastatic castration-sensitive prostate cancer setting.Medscape Medical News
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Hematology-Oncology News Alert Source Type: news